{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T04:17:04Z","timestamp":1792729024212,"version":"4.5.0"},"reference-count":149,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T00:00:00Z","timestamp":1744243200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Rev Microbiol"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1038\/s41579-025-01169-8","type":"journal-article","created":{"date-parts":[[2025,4,10]],"date-time":"2025-04-10T07:53:14Z","timestamp":1744271594000},"page":"491-508","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":76,"title":["The global resistance problem and the clinical antibacterial pipeline"],"prefix":"10.1038","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-2116-7128","authenticated-orcid":false,"given":"Ursula","family":"Theuretzbacher","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,4,10]]},"reference":[{"key":"1169_CR1","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1038\/s41579-024-01080-8","volume":"22","author":"U Theuretzbacher","year":"2024","unstructured":"Theuretzbacher, U. Challenges and strategies for addressing antibacterial drug resistance in LMICs. Nat. Rev. Microbiol. 22, 591\u2013592 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1169_CR2","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/s41579-024-01083-5","volume":"22","author":"M Balasegaram","year":"2024","unstructured":"Balasegaram, M. & Mu\u00f1oz Tellez, V. Achieving sustainable access to antibiotics is more than just a last mile challenge. Nat. Rev. Microbiol. 22, 593\u2013594 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1169_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/s41579-024-01076-4","volume":"22","author":"D Cocker","year":"2024","unstructured":"Cocker, D. et al. Healthcare as a driver, reservoir and amplifier of antimicrobial resistance: opportunities for interventions. Nat. Rev. Microbiol. 22, 636\u2013649 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1169_CR4","doi-asserted-by":"publisher","first-page":"e516","DOI":"10.1016\/S2214-109X(23)00554-5","volume":"12","author":"M Mendelson","year":"2024","unstructured":"Mendelson, M. et al. Antimicrobial resistance and the great divide: inequity in priorities and agendas between the Global North and the Global South threatens global mitigation of antimicrobial resistance. Lancet Glob. Health 12, e516\u2013e521 (2024).","journal-title":"Lancet Glob. Health"},{"key":"1169_CR5","doi-asserted-by":"publisher","first-page":"1914","DOI":"10.3389\/fmicb.2020.01914","volume":"11","author":"S Hernando-Amado","year":"2020","unstructured":"Hernando-Amado, S., Coque, T. M., Baquero, F. & Mart\u00ednez, J. L. Antibiotic resistance: moving from individual health norms to social norms in one health and global health. Front. Microbiol. 11, 1914 (2020).","journal-title":"Front. Microbiol."},{"key":"1169_CR6","doi-asserted-by":"publisher","first-page":"2426","DOI":"10.1016\/S0140-6736(24)00876-6","volume":"403","author":"IN Okeke","year":"2024","unstructured":"Okeke, I. N. et al. The scope of the antimicrobial resistance challenge. Lancet 403, 2426\u20132438 (2024).","journal-title":"Lancet"},{"key":"1169_CR7","doi-asserted-by":"publisher","first-page":"2068","DOI":"10.1017\/ice.2023.116","volume":"44","author":"DR Brown","year":"2023","unstructured":"Brown, D. R., Henderson, H. I., Ruegsegger, L., Moody, J. & van Duin, D. Socioeconomic disparities in the prevalence of multidrug resistance in Enterobacterales. Infect. Control Hosp. Epidemiol. 44, 2068\u20132070 (2023).","journal-title":"Infect. Control Hosp. Epidemiol."},{"key":"1169_CR8","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-018-0459-7","volume":"7","author":"V Alividza","year":"2018","unstructured":"Alividza, V. et al. Investigating the impact of poverty on colonization and infection with drug-resistant organisms in humans: a systematic review. Infect. Dis. Poverty 7, 76 (2018).","journal-title":"Infect. Dis. Poverty"},{"key":"1169_CR9","first-page":"204993612199137","volume":"8","author":"JP Burnham","year":"2021","unstructured":"Burnham, J. P. Climate change and antibiotic resistance: a deadly combination. Ther. Adv. Infect. Dis. 8, 204993612199137 (2021).","journal-title":"Ther. Adv. Infect. Dis."},{"key":"1169_CR10","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1016\/j.jgar.2024.03.020","volume":"37","author":"MG Wise","year":"2024","unstructured":"Wise, M. G. et al. Global trends in carbapenem- and difficult-to-treat-resistance among World Health Organization priority bacterial pathogens: ATLAS surveillance program 2018\u20132022. J. Glob. Antimicrob. Resist. 37, 168\u2013175 (2024).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"1169_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1007\/s40121-020-00395-2","volume":"10","author":"GT Hansen","year":"2021","unstructured":"Hansen, G. T. Continuous evolution: perspective on the epidemiology of carbapenemase resistance among enterobacterales and other gram-negative bacteria. Infect. Dis. Ther. 10, 75\u201392 (2021).","journal-title":"Infect. Dis. Ther."},{"key":"1169_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40249-022-01016-5","volume":"11","author":"N Zhou","year":"2022","unstructured":"Zhou, N. et al. Global antimicrobial resistance: a system-wide comprehensive investigation using the Global One Health Index. Infect. Dis. Poverty 11, 92 (2022).","journal-title":"Infect. Dis. Poverty"},{"key":"1169_CR13","doi-asserted-by":"publisher","first-page":"2439","DOI":"10.1016\/S0140-6736(24)00862-6","volume":"403","author":"JA Lewnard","year":"2024","unstructured":"Lewnard, J. A. et al. Burden of bacterial antimicrobial resistance in low-income and middle-income countries avertible by existing interventions: an evidence review and modelling analysis. Lancet 403, 2439\u20132454 (2024).","journal-title":"Lancet"},{"key":"1169_CR14","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","volume":"404","author":"M Naghavi","year":"2024","unstructured":"Naghavi, M. et al. Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050. Lancet 404, 1199\u20131226 (2024).","journal-title":"Lancet"},{"key":"1169_CR15","doi-asserted-by":"publisher","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","volume":"399","author":"CJL Murray","year":"2022","unstructured":"Murray, C. J. L. et al. Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis. Lancet 399, 629\u2013655 (2022).","journal-title":"Lancet"},{"key":"1169_CR16","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","volume":"400","author":"KS Ikuta","year":"2022","unstructured":"Ikuta, K. S. et al. Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet 400, 2221\u20132248 (2022).","journal-title":"Lancet"},{"key":"1169_CR17","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1016\/S1473-3099(17)30753-3","volume":"18","author":"E Tacconelli","year":"2018","unstructured":"Tacconelli, E. et al. Discovery, research, and development of new antibiotics: the WHO priority list of antibiotic-resistant bacteria and tuberculosis. Lancet Infect. Dis. 18, 318\u2013327 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"1169_CR18","doi-asserted-by":"publisher","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","volume":"22","author":"WR Miller","year":"2024","unstructured":"Miller, W. R. & Arias, C. A. ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics. Nat. Rev. Microbiol. 22, 598\u2013616 (2024).","journal-title":"Nat. Rev. Microbiol."},{"key":"1169_CR19","doi-asserted-by":"publisher","first-page":"1131","DOI":"10.1016\/j.cmi.2024.06.016","volume":"30","author":"M Hoelscher","year":"2024","unstructured":"Hoelscher, M. et al. Candidate anti-tuberculosis medicines and regimens under clinical evaluation. Clin. Microbiol. Infect. 30, 1131\u20131138 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"1169_CR20","unstructured":"World Health Organization. Global tuberculosis report 2023: TB research and innovation. WHO https:\/\/www.who.int\/teams\/global-programme-on-tuberculosis-and-lung-health\/tb-reports\/global-tuberculosis-report-2023\/tb-research-and-innovation (2023)."},{"key":"1169_CR21","doi-asserted-by":"publisher","first-page":"127249","DOI":"10.1016\/j.micres.2022.127249","volume":"266","author":"J Ma","year":"2023","unstructured":"Ma, J. et al. Global spread of carbapenem-resistant Enterobacteriaceae: epidemiological features, resistance mechanisms, detection and therapy. Microbiol. Res. 266, 127249 (2023).","journal-title":"Microbiol. Res."},{"key":"1169_CR22","doi-asserted-by":"publisher","first-page":"1715","DOI":"10.1007\/s40121-024-00995-2","volume":"13","author":"KS Kaye","year":"2024","unstructured":"Kaye, K. S. et al. Co-resistance among Escherichia coli and Klebsiella pneumoniae urine isolates from female outpatients with presumed UTI: a retrospective US cohort study. Infect. Dis. Ther. 13, 1715\u20131722 (2024).","journal-title":"Infect. Dis. Ther."},{"key":"1169_CR23","doi-asserted-by":"publisher","first-page":"107113","DOI":"10.1016\/j.ijantimicag.2024.107113","volume":"63","author":"HS Sader","year":"2024","unstructured":"Sader, H. S., Carvalhaes, C. G., Kimbrough, J. H., Mendes, R. E. & Castanheira, M. Activity of aztreonam-avibactam against Enterobacterales resistant to recently approved beta-lactamase inhibitor combinations collected in Europe, Latin America, and the Asia-Pacific Region (2020\u20132022). Int. J. Antimicrob. Agents 63, 107113 (2024).","journal-title":"Int. J. Antimicrob. Agents"},{"key":"1169_CR24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.1007\/s10096-023-04647-0","volume":"42","author":"P Nordmann","year":"2023","unstructured":"Nordmann, P., Bouvier, M. & Poirel, L. Efficacy of ceftazidime\u2013avibactam, meropenem\u2013vaborbactam, and imipenem\u2013relebactam combinations against carbapenemase-producing Enterobacterales in Switzerland. Eur. J. Clin. Microbiol. Infect. Dis. 42, 1145\u20131152 (2023).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"1169_CR25","doi-asserted-by":"publisher","first-page":"10.1128","DOI":"10.1128\/mSphere.00074-19","volume":"4","author":"S Ranjitkar","year":"2019","unstructured":"Ranjitkar, S. et al. Identification of mutations in the mrdA gene encoding PBP2 that reduce carbapenem and diazabicyclooctane susceptibility of Escherichia coli clinical isolates with mutations in ftsI (PBP3) and which carry bla NDM-1. mSphere 4, 10.1128 (2019).","journal-title":"mSphere"},{"key":"1169_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01548-23","volume":"68","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier, C., Nordmann, P., Buchs, C. & Poirel, L. Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime\u2013avibactam, imipenem\u2013relebactam, meropenem\u2013vaborbactam, aztreonam\u2013avibactam, cefepime\u2013taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum \u03b2-lactamases. Antimicrob. Agents Chemother. 68, e0154823 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR27","doi-asserted-by":"publisher","first-page":"e02705","DOI":"10.1128\/mBio.02705-20","volume":"12","author":"E Bordeleau","year":"2021","unstructured":"Bordeleau, E. et al. ApmA is a unique aminoglycoside antibiotic acetyltransferase that inactivates apramycin. mBio 12, e02705\u2013e02720 (2021).","journal-title":"mBio"},{"key":"1169_CR28","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.cmi.2023.08.029","volume":"30","author":"S Karakonstantis","year":"2024","unstructured":"Karakonstantis, S., Rousaki, M., Vassilopoulou, L. & Kritsotakis, E. I. Global prevalence of cefiderocol non-susceptibility in Enterobacterales, Pseudomonas aeruginosa, Acinetobacter baumannii, and Stenotrophomonas maltophilia: a systematic review and meta-analysis. Clin. Microbiol. Infect. 30, 178\u2013188 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"1169_CR29","first-page":"S166","volume":"76","author":"M Castanheira","year":"2023","unstructured":"Castanheira, M., Mendes, R. E. & Gales, A. C. Global epidemiology and mechanisms of resistance of Acinetobacter baumannii\u2013calcoaceticus complex. Clin. Microbiol. Infect. 76, S166\u2013S178 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"1169_CR30","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1011520","volume":"19","author":"AK Cain","year":"2023","unstructured":"Cain, A. K. & Hamidian, M. Portrait of a killer: uncovering resistance mechanisms and global spread of Acinetobacter baumannii. PLoS Pathog. 19, e1011520 (2023).","journal-title":"PLoS Pathog."},{"key":"1169_CR31","doi-asserted-by":"publisher","first-page":"6814","DOI":"10.3390\/ijms25136814","volume":"25","author":"A Marino","year":"2024","unstructured":"Marino, A. et al. Unveiling the secrets of Acinetobacter baumannii: resistance, current treatments, and future innovations. Int. J. Mol. Sci. 25, 6814 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1169_CR32","doi-asserted-by":"publisher","first-page":"1458","DOI":"10.1021\/acsinfecdis.4c00091","volume":"10","author":"M Duffey","year":"2024","unstructured":"Duffey, M. et al. Extending the potency and lifespan of antibiotics: inhibitors of Gram-negative bacterial efflux pumps. ACS Infect. Dis. 10, 1458\u20131482 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR33","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3390\/antibiotics12111590","volume":"12","author":"A Gauba","year":"2023","unstructured":"Gauba, A. & Rahman, K. M. Evaluation of antibiotic resistance mechanisms in Gram-negative bacteria. Antibiotics 12, 1590 (2023).","journal-title":"Antibiotics"},{"key":"1169_CR34","doi-asserted-by":"publisher","first-page":"1374466","DOI":"10.3389\/fmicb.2024.1374466","volume":"15","author":"A Elfadadny","year":"2024","unstructured":"Elfadadny, A. et al. Antimicrobial resistance of Pseudomonas aeruginosa: navigating clinical impacts, current resistance trends, and innovations in breaking therapies. Front. Microbiol. 15, 1374466 (2024).","journal-title":"Front. Microbiol."},{"key":"1169_CR35","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1016\/j.cmi.2023.12.026","volume":"30","author":"A Oliver","year":"2024","unstructured":"Oliver, A. et al. Pseudomonas aeruginosa antimicrobial susceptibility profiles, resistance mechanisms and international clonal lineages: update from ESGARS-ESCMID\/ISARPAE Group. Clin. Microbiol. Infect. 30, 469\u2013480 (2024).","journal-title":"Clin. Microbiol. Infect."},{"key":"1169_CR36","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/s43856-024-00591-y","volume":"4","author":"A Dulanto Chiang","year":"2024","unstructured":"Dulanto Chiang, A. & Dekker, J. P. Efflux pump-mediated resistance to new beta lactam antibiotics in multidrug-resistant Gram-negative bacteria. Commun. Med. 4, 170 (2024).","journal-title":"Commun. Med."},{"key":"1169_CR37","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01363-23","volume":"68","author":"M Castanheira","year":"2024","unstructured":"Castanheira, M. et al. In vitro development of resistance against antipseudomonal agents: comparison of novel \u03b2-lactam\/\u03b2-lactamase inhibitor combinations and other \u03b2-lactam agents. Antimicrob. Agents Chemother. 68, e0136323 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR38","doi-asserted-by":"publisher","first-page":"61","DOI":"10.1016\/j.chom.2019.06.004","volume":"26","author":"U Theuretzbacher","year":"2019","unstructured":"Theuretzbacher, U. & Piddock, L. J. V. Non-traditional antibacterial therapeutic options and challenges. Cell Host Microbe 26, 61\u201372 (2019).","journal-title":"Cell Host Microbe"},{"key":"1169_CR39","doi-asserted-by":"publisher","first-page":"59","DOI":"10.3390\/antibiotics13010059","volume":"13","author":"LMC Jacobs","year":"2024","unstructured":"Jacobs, L. M. C., Consol, P. & Chen, Y. Drug discovery in the field of \u03b2-lactams: an academic perspective. Antibiotics 13, 59 (2024).","journal-title":"Antibiotics"},{"key":"1169_CR40","doi-asserted-by":"publisher","first-page":"i47","DOI":"10.1093\/jac\/dkaa497","volume":"76","author":"U Theuretzbacher","year":"2021","unstructured":"Theuretzbacher, U., Carrara, E., Conti, M. & Tacconelli, E. Role of new antibiotics for KPC-producing Klebsiella pneumoniae. J. Antimicrob. Chemother. 76, i47\u2013i54 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR41","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01120-23","volume":"68","author":"M Zalacain","year":"2024","unstructured":"Zalacain, M. et al. Meropenem-ANT3310, a unique \u03b2-lactam-\u03b2-lactamase inhibitor combination with expanded antibacterial spectrum against Gram-negative pathogens including carbapenem-resistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 68, e0112023 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR42","doi-asserted-by":"publisher","first-page":"7491","DOI":"10.1021\/acs.jmedchem.9b01976","volume":"63","author":"SJ Hecker","year":"2020","unstructured":"Hecker, S. J. et al. Discovery of cyclic boronic acid QPX7728, an ultrabroad-spectrum inhibitor of serine and metallo-\u03b2-lactamases. J. Med. Chem. 63, 7491\u20137507 (2020).","journal-title":"J. Med. Chem."},{"key":"1169_CR43","doi-asserted-by":"publisher","first-page":"2789","DOI":"10.1021\/acs.jmedchem.9b01518","volume":"63","author":"B Liu","year":"2020","unstructured":"Liu, B. et al. Discovery of taniborbactam (VNRX-5133): a broad-spectrum serine- and metallo-\u03b2-lactamase inhibitor for carbapenem-resistant bacterial infections. J. Med. Chem. 63, 2789\u20132801 (2020).","journal-title":"J. Med. Chem."},{"key":"1169_CR44","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00440-23","volume":"67","author":"O Lomovskaya","year":"2023","unstructured":"Lomovskaya, O. et al. In vitro potency of xeruborbactam in combination with multiple \u03b2-lactam antibiotics in comparison with other \u03b2-lactam\/\u03b2-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum \u03b2-lactamase-producing Enterobacterales. Antimicrob. Agents Chemother. 67, e0044023 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR45","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms12406","volume":"7","author":"J Brem","year":"2016","unstructured":"Brem, J. et al. Structural basis of metallo-\u03b2-lactamase, serine-\u03b2-lactamase and penicillin-binding protein inhibition by cyclic boronates. Nat. Commun. 7, 12406 (2016).","journal-title":"Nat. Commun."},{"key":"1169_CR46","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01570-23","volume":"68","author":"C Le Terrier","year":"2024","unstructured":"Le Terrier, C., Viguier, C., Nordmann, P., Vila, A. J. & Poirel, L. Relative inhibitory activities of the broad-spectrum \u03b2-lactamase inhibitor taniborbactam against metallo-\u03b2-lactamases. Antimicrob. Agents Chemother. 68, e0157023 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR47","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01168-23","volume":"68","author":"SI Drusin","year":"2024","unstructured":"Drusin, S. I. et al. Structural basis of metallo-\u03b2-lactamase resistance to taniborbactam. Antimicrob. Agents Chemother. 68, e0116823 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jgar.2022.07.006","volume":"31","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. In vitro and in vivo activities of a novel \u03b2-lactamase inhibitor combination imipenem\/XNW4107 against recent clinical Gram-negative bacilli from China. J. Glob. Antimicrob. Resist. 31, 1\u20139 (2022).","journal-title":"J. Glob. Antimicrob. Resist."},{"key":"1169_CR49","doi-asserted-by":"publisher","first-page":"1282480","DOI":"10.3389\/fphar.2024.1282480","volume":"15","author":"Z Huang","year":"2024","unstructured":"Huang, Z. et al. In vitro pharmacokinetics\/pharmacodynamics of FL058 (a novel beta-lactamase inhibitor) combined with meropenem against carbapenemase-producing Enterobacterales. Front. Pharmacol. 15, 1282480 (2024).","journal-title":"Front. Pharmacol."},{"key":"1169_CR50","first-page":"e01602","volume":"68","author":"K Takemoto","year":"2024","unstructured":"Takemoto, K. et al. In vitro and in vivo activities of KSP-1007, a broad-spectrum inhibitor of serine- and metallo-\u03b2-lactamases, in combination with meropenem against carbapenem-resistant Gram-negative bacteria. Antimicrob. Agents Chemother. 68, e01602\u2013e01623 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR51","doi-asserted-by":"publisher","first-page":"7957","DOI":"10.1021\/acs.chemrev.1c00138","volume":"121","author":"G Bahr","year":"2021","unstructured":"Bahr, G., Gonz\u00e1lez, L. J. & Vila, A. J. Metallo-\u03b2-lactamases in the age of multidrug resistance: from structure and mechanism to evolution, dissemination, and inhibitor design. Chem. Rev. 121, 7957\u20138094 (2021).","journal-title":"Chem. Rev."},{"key":"1169_CR52","doi-asserted-by":"publisher","first-page":"e00397","DOI":"10.1128\/AAC.00397-20","volume":"64","author":"SE Boyd","year":"2020","unstructured":"Boyd, S. E., Livermore, D. M., Hooper, D. C. & Hope, W. W. Metallo-\u03b2-lactamases: structure, function, epidemiology, treatment options, and the development pipeline. Antimicrob. Agents Chemother. 64, e00397\u201320 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR53","doi-asserted-by":"publisher","first-page":"e02415","DOI":"10.1128\/AAC.02415-19","volume":"64","author":"\u00d8 Samuelsen","year":"2020","unstructured":"Samuelsen, \u00d8. et al. ZN148 is a modular synthetic metallo-\u03b2-lactamase inhibitor that reverses carbapenem resistance in Gram-negative pathogens in vivo. Antimicrob. Agents Chemother. 64, e02415\u2013e02419 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR54","doi-asserted-by":"publisher","first-page":"2546","DOI":"10.1093\/jac\/dkab213","volume":"76","author":"I Barcel\u00f3","year":"2021","unstructured":"Barcel\u00f3, I. et al. In vitro evolution of cefepime\/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy. J. Antimicrob. Chemother. 76, 2546\u20132557 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR55","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.02678-21","volume":"10","author":"X Pan","year":"2022","unstructured":"Pan, X. et al. Molecular characterization of WCK 5222 (cefepime\/zidebactam)-resistant mutants developed from a carbapenem-resistant Pseudomonas aeruginosa clinical isolate. Microbiol. Spectr. 10, e0267821 (2022).","journal-title":"Microbiol. Spectr."},{"key":"1169_CR56","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1093\/jac\/dkad033","volume":"78","author":"Y Igarashi","year":"2023","unstructured":"Igarashi, Y. et al. Development of an optimized and practical pharmacokinetics\/pharmacodynamics analysis method for aztreonam\/nacubactam against carbapenemase-producing K. pneumoniae. J. Antimicrob. Chemother. 78, 991\u2013999 (2023).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR57","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1007\/s11908-024-00831-1","volume":"26","author":"BR Mangum","year":"2024","unstructured":"Mangum, B. R., Pogue, J. M. & Barber, K. E. Tebipenem and sulopenem: dynamic duo or double trouble? Curr. Infect. Dis. Rep. 26, 139\u2013150 (2024).","journal-title":"Curr. Infect. Dis. Rep."},{"key":"1169_CR58","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1007\/s40265-022-01688-1","volume":"82","author":"GG Zhanel","year":"2022","unstructured":"Zhanel, G. G. et al. Sulopenem: an intravenous and oral penem for the treatment of urinary tract infections due to multidrug-resistant bacteria. Drugs 82, 533\u2013557 (2022).","journal-title":"Drugs"},{"key":"1169_CR59","unstructured":"Spero Therapeutics. Spero Therapeutics receives complete response letter from US Food and Drug Administration for tebipenem HBr new drug application. GlobeNewsWire https:\/\/www.globenewswire.com\/news-release\/2022\/06\/27\/2469890\/0\/en\/Spero-Therapeutics-Receives-Complete-Response-Letter-from-U-S-Food-and-Drug-Administration-for-Tebipenem-HBr-New-Drug-Application.html (2022)."},{"key":"1169_CR60","unstructured":"Iterum therapeutics. Iterum therapeutics provides update on FDA advisory committee discussion of oral sulopenem for the treatment of uUTI in adult women. Iterum Therapeutics https:\/\/www.iterumtx.com\/news\/press-releases\/detail\/133\/iterum-therapeutics-provides-update-on-fda-advisory (2024)."},{"key":"1169_CR61","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01346-22","volume":"67","author":"JA Karlowsky","year":"2023","unstructured":"Karlowsky, J. A., Hackel, M. A., Stone, G. G. & Sahm, D. F. In vitro activity of ceftibuten\u2013avibactam against \u03b2-lactamase-positive enterobacterales from the ATLAS global surveillance program. Antimicrob. Agents Chemother. 67, e0134622 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR62","doi-asserted-by":"publisher","first-page":"453","DOI":"10.1007\/s10096-023-04562-4","volume":"42","author":"HS Sader","year":"2023","unstructured":"Sader, H. S., Carvalhaes, C. G., Huband, M. D., Mendes, R. E. & Castanheira, M. Antimicrobial activity of ceftibuten\u2013avibactam against a global collection of Enterobacterales from patients with urinary tract infections (2021). Eur. J. Clin. Microbiol. Infect. Dis. 42, 453\u2013459 (2023).","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"1169_CR63","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00934-22","volume":"66","author":"JA Karlowsky","year":"2022","unstructured":"Karlowsky, J. A. et al. Ceftibuten\u2013ledaborbactam activity against multidrug-resistant and extended-spectrum-\u03b2-lactamase-positive clinical isolates of Enterobacterales from a 2018\u20132020 global surveillance collection. Antimicrob. Agents Chemother. 66, e0093422 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR64","doi-asserted-by":"publisher","first-page":"1056","DOI":"10.1021\/acsinfecdis.3c00630","volume":"10","author":"CJ Slingerland","year":"2024","unstructured":"Slingerland, C. J. & Martin, N. I. Recent advances in the development of polymyxin antibiotics: 2010\u20132023. ACS Infect. Dis. 10, 1056\u20131079 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR65","doi-asserted-by":"publisher","first-page":"772","DOI":"10.3390\/microorganisms12040772","volume":"12","author":"AH Mondal","year":"2024","unstructured":"Mondal, A. H. et al. A review on colistin resistance: an antibiotic of last resort. Microorganisms 12, 772 (2024).","journal-title":"Microorganisms"},{"key":"1169_CR66","doi-asserted-by":"publisher","first-page":"1762","DOI":"10.1093\/jac\/dkae130","volume":"79","author":"SK Dwibedy","year":"2024","unstructured":"Dwibedy, S. K., Padhy, I., Panda, A. K. & Mohapatra, S. S. Prevalence of polymyxin-resistant bacterial strains in India: a systematic review and meta-analysis. J. Antimicrob. Chemother. 79, 1762\u20131774 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR67","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00739-21","volume":"65","author":"J Bruss","year":"2021","unstructured":"Bruss, J. et al. Single- and multiple-ascending-dose study of the safety, tolerability, and pharmacokinetics of the polymyxin derivative SPR206. Antimicrob. Agents Chemother. 65, e0073921 (2021).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR68","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-29234-3","volume":"13","author":"KD Roberts","year":"2022","unstructured":"Roberts, K. D. et al. A synthetic lipopeptide targeting top-priority multidrug-resistant Gram-negative pathogens. Nat. Commun. 13, 1625 (2022).","journal-title":"Nat. Commun."},{"key":"1169_CR69","doi-asserted-by":"publisher","first-page":"354","DOI":"10.3390\/antibiotics13040354","volume":"13","author":"X Qu","year":"2024","unstructured":"Qu, X. et al. Pharmacokinetics and nephrotoxicity of polymyxin MRX-8 in rats: a novel agent against resistant Gram-negative bacteria. Antibiotics 13, 354 (2024).","journal-title":"Antibiotics"},{"key":"1169_CR70","doi-asserted-by":"publisher","DOI":"10.1128\/aac.00139-22","volume":"66","author":"LR Duncan","year":"2022","unstructured":"Duncan, L. R., Wang, W. & Sader, H. S. In vitro potency and spectrum of the novel polymyxin MRX-8 tested against clinical isolates of Gram-negative bacteria. Antimicrob. Agents Chemother. 66, e0013922 (2022).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR71","doi-asserted-by":"publisher","first-page":"2017","DOI":"10.1093\/jac\/dkab131","volume":"76","author":"M Hao","year":"2021","unstructured":"Hao, M. et al. Apramycin resistance in epidemic carbapenem-resistant Klebsiella pneumoniae ST258 strains. J. Antimicrob. Chemother. 76, 2017\u20132023 (2021).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR72","doi-asserted-by":"publisher","first-page":"3552","DOI":"10.1093\/jac\/dkaa370","volume":"75","author":"V Trebosc","year":"2020","unstructured":"Trebosc, V. et al. In vitro activity of rifabutin against 293 contemporary carbapenem-resistant Acinetobacter baumannii clinical isolates and characterization of rifabutin mode of action and resistance mechanisms. J. Antimicrob. Chemother. 75, 3552\u20133562 (2020).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR73","doi-asserted-by":"publisher","first-page":"753","DOI":"10.1248\/bpb.35.753","volume":"35","author":"T Funahashi","year":"2012","unstructured":"Funahashi, T. et al. Identification and characterization of an outer membrane receptor gene in Acinetobacter baumannii required for utilization of desferricoprogen, rhodotorulic acid, and desferrioxamine B as xenosiderophores. Biol. Pharm. Bull. 35, 753\u2013760 (2012).","journal-title":"Biol. Pharm. Bull."},{"key":"1169_CR74","doi-asserted-by":"publisher","first-page":"6645","DOI":"10.1021\/acs.jmedchem.6b00485","volume":"59","author":"Z Ma","year":"2016","unstructured":"Ma, Z. & Lynch, A. S. Development of a dual-acting antibacterial agent (TNP-2092) for the treatment of persistent bacterial infections. J. Med. Chem. 59, 6645\u20136657 (2016).","journal-title":"J. Med. Chem."},{"key":"1169_CR75","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/S1473-3099(24)00003-3","volume":"24","author":"X Li","year":"2024","unstructured":"Li, X. et al. Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials. Lancet Infect. Dis. 24, 650\u2013664 (2024).","journal-title":"Lancet Infect. Dis."},{"key":"1169_CR76","doi-asserted-by":"publisher","first-page":"114490","DOI":"10.1016\/j.ejmech.2022.114490","volume":"238","author":"N Sza\u0142aj","year":"2022","unstructured":"Sza\u0142aj, N. et al. Bacterial type I signal peptidase inhibitors \u2014 optimized hits from nature. Eur. J. Med. Chem. 238, 114490 (2022).","journal-title":"Eur. J. Med. Chem."},{"key":"1169_CR77","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-021-86155-9","volume":"11","author":"S Mandel","year":"2021","unstructured":"Mandel, S. et al. OMN6 a novel bioengineered peptide for the treatment of multidrug resistant Gram-negative bacteria. Sci. Rep. 11, 6603 (2021).","journal-title":"Sci. Rep."},{"key":"1169_CR78","doi-asserted-by":"publisher","first-page":"566","DOI":"10.1038\/s41586-023-06873-0","volume":"625","author":"C Zampaloni","year":"2024","unstructured":"Zampaloni, C. et al. A novel antibiotic class targeting the lipopolysaccharide transporter. Nature 625, 566\u2013571 (2024).","journal-title":"Nature"},{"key":"1169_CR79","doi-asserted-by":"publisher","first-page":"4290","DOI":"10.1128\/AAC.00613-16","volume":"60","author":"M Kaul","year":"2016","unstructured":"Kaul, M., Mark, L., Parhi, A. K., LaVoie, E. J. & Pilch, D. S. Combining the FtsZ-targeting prodrug TXA709 and the cephalosporin cefdinir confers synergy and reduces the frequency of resistance in methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 60, 4290\u20134296 (2016).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR80","doi-asserted-by":"publisher","first-page":"e00863","DOI":"10.1128\/AAC.00863-17","volume":"61","author":"E Ferrer-Gonz\u00e1lez","year":"2017","unstructured":"Ferrer-Gonz\u00e1lez, E., Kaul, M., Parhi, A. K., LaVoie, E. J. & Pilch, D. S. \u03b2-Lactam antibiotics with a high affinity for PBP2 act synergistically with the FtsZ-targeting agent TXA707 against methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 61, e00863\u201317 (2017).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR81","doi-asserted-by":"publisher","first-page":"5865","DOI":"10.1128\/AAC.01411-12","volume":"56","author":"N Kaplan","year":"2012","unstructured":"Kaplan, N. et al. Mode of action, in vitro activity, and in vivo efficacy of AFN-1252, a selective antistaphylococcal fabi inhibitor. Antimicrob. Agents Chemother. 56, 5865\u20135874 (2012).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR82","doi-asserted-by":"publisher","first-page":"36261","DOI":"10.1074\/jbc.M113.512905","volume":"288","author":"J Yao","year":"2013","unstructured":"Yao, J., Maxwell, J. B. & Rock, C. O. Resistance to AFN-1252 arises from missense mutations in Staphylococcus aureus enoyl-acyl carrier protein reductase (FabI). J. Biol. Chem. 288, 36261\u201336271 (2013).","journal-title":"J. Biol. Chem."},{"key":"1169_CR83","doi-asserted-by":"publisher","first-page":"e00250","DOI":"10.1128\/AAC.00250-20","volume":"64","author":"F Wittke","year":"2020","unstructured":"Wittke, F. et al. Afabicin, a first-in-class antistaphylococcal antibiotic, in the treatment of acute bacterial skin and skin structure infections: clinical noninferiority to vancomycin\/linezolid. Antimicrob. Agents Chemother. 64, e00250\u201320 (2020).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR84","first-page":"100017","volume":"3","author":"J Desai","year":"2021","unstructured":"Desai, J., S, S., Kumar, S. & Sharma, R. Novel bacterial topoisomerase inhibitors (NBTIs) \u2014 a comprehensive review. Eur. J. Med. Chem. Rep. 3, 100017 (2021).","journal-title":"Eur. J. Med. Chem. Rep."},{"key":"1169_CR85","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1021\/acsinfecdis.4c00438","volume":"10","author":"JA Collins","year":"2024","unstructured":"Collins, J. A., Basarab, G. S., Chibale, K. & Osheroff, N. Interactions between zoliflodacin and neisseria gonorrhoeae gyrase and topoisomerase IV: enzymological basis for cellular targeting. ACS Infect. Dis. 10, 3071\u20133082 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR86","doi-asserted-by":"publisher","first-page":"1137","DOI":"10.1021\/acsinfecdis.3c00346","volume":"10","author":"AA Oviatt","year":"2024","unstructured":"Oviatt, A. A. et al. Interactions between gepotidacin and Escherichia coli gyrase and topoisomerase IV: genetic and biochemical evidence for well-balanced dual-targeting. ACS Infect. Dis. 10, 1137\u20131151 (2024).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR87","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01525-22","volume":"67","author":"SJR Arends","year":"2023","unstructured":"Arends, S. J. R., Butler, D., Scangarella-Oman, N., Castanheira, M. & Mendes, R. E. Antimicrobial activity of gepotidacin tested against Escherichia coli and Staphylococcus saprophyticus isolates causing urinary tract infections in medical centers worldwide (2019 to 2020). Antimicrob. Agents Chemother. 67, e0152522 (2023).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR88","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.00207-19","volume":"63","author":"P Szili","year":"2019","unstructured":"Szili, P. et al. Rapid evolution of reduced susceptibility against a balanced dual-targeting antibiotic through stepping-stone mutations. Antimicrob. Agents Chemother. 63, e0152522 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR89","doi-asserted-by":"publisher","first-page":"2307","DOI":"10.1007\/s40121-023-00862-6","volume":"12","author":"CR Perry","year":"2023","unstructured":"Perry, C. R. et al. Efficacy and safety of gepotidacin as treatment of uncomplicated urogenital gonorrhea (EAGLE-1): design of a randomized, comparator-controlled, phase 3 study. Infect. Dis. Ther. 12, 2307\u20132320 (2023).","journal-title":"Infect. Dis. Ther."},{"key":"1169_CR90","unstructured":"Nandishaiah, R. et al. Molecular interactions of BWC0977; a dual inhibitor of DNA gyrase and topoisomerase IV. In Proc. Congress of the European Society of Clinical Microbiology and Infectious Diseases (ECCMID, 2023)."},{"key":"1169_CR91","doi-asserted-by":"publisher","first-page":"1332","DOI":"10.1021\/acsinfecdis.0c00021","volume":"6","author":"PA Bradford","year":"2020","unstructured":"Bradford, P. A., Miller, A. A., O\u2019Donnell, J. & Mueller, J. P. Zoliflodacin: an oral spiropyrimidinetrione antibiotic for the treatment of Neisseria gonorrheae, including multi-drug-resistant isolates. ACS Infect. Dis. 6, 1332\u20131345 (2020).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR92","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-49943-z","volume":"14","author":"S Abdellati","year":"2024","unstructured":"Abdellati, S. et al. Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study. Sci. Rep. 14, 1179 (2024).","journal-title":"Sci. Rep."},{"key":"1169_CR93","doi-asserted-by":"publisher","first-page":"765","DOI":"10.3390\/biomedicines11030765","volume":"11","author":"K Kharga","year":"2023","unstructured":"Kharga, K., Kumar, L. & Patel, S. K. S. Recent advances in monoclonal antibody-based approaches in the management of bacterial sepsis. Biomedicines 11, 765 (2023).","journal-title":"Biomedicines"},{"key":"1169_CR94","doi-asserted-by":"publisher","first-page":"916","DOI":"10.3390\/microorganisms11040916","volume":"11","author":"MM Elmassry","year":"2023","unstructured":"Elmassry, M. M., Colmer-Hamood, J. A., Kopel, J., San Francisco, M. J. & Hamood, A. N. Anti-Pseudomonas aeruginosa vaccines and therapies: an assessment of clinical trials. Microorganisms 11, 916 (2023).","journal-title":"Microorganisms"},{"key":"1169_CR95","doi-asserted-by":"publisher","first-page":"2179","DOI":"10.1021\/acscentsci.3c01474","volume":"9","author":"G Brodie","year":"2023","unstructured":"Brodie, G. & Conway, S. J. Disarming Gram-negative bacteria in the fight against antimicrobial resistance. ACS Cent. Sci. 9, 2179\u20132182 (2023).","journal-title":"ACS Cent. Sci."},{"key":"1169_CR96","doi-asserted-by":"publisher","first-page":"5487","DOI":"10.3390\/ijms25105487","volume":"25","author":"C La Guidara","year":"2024","unstructured":"La Guidara, C., Adamo, R., Sala, C. & Micoli, F. Vaccines and monoclonal antibodies as alternative strategies to antibiotics to fight antimicrobial resistance. Int. J. Mol. Sci. 25, 5487 (2024).","journal-title":"Int. J. Mol. Sci."},{"key":"1169_CR97","doi-asserted-by":"publisher","first-page":"246","DOI":"10.3390\/life14020246","volume":"14","author":"H-C Chen","year":"2024","unstructured":"Chen, H.-C. et al. Monoclonal antibodies as a therapeutic strategy against multidrug-resistant bacterial infections in a post-COVID-19 era. Life 14, 246 (2024).","journal-title":"Life"},{"key":"1169_CR98","doi-asserted-by":"publisher","first-page":"2126","DOI":"10.3390\/biomedicines10092126","volume":"10","author":"F Vacca","year":"2022","unstructured":"Vacca, F., Sala, C. & Rappuoli, R. Monoclonal antibodies for bacterial pathogens: mechanisms of action and engineering approaches for enhanced effector functions. Biomedicines 10, 2126 (2022).","journal-title":"Biomedicines"},{"key":"1169_CR99","doi-asserted-by":"publisher","first-page":"5740","DOI":"10.1016\/j.cell.2021.10.010","volume":"184","author":"JR Buzzo","year":"2021","unstructured":"Buzzo, J. R. et al. Z-form extracellular DNA is a structural component of the bacterial biofilm matrix. Cell 184, 5740\u20135758.e17 (2021).","journal-title":"Cell"},{"key":"1169_CR100","doi-asserted-by":"publisher","first-page":"104","DOI":"10.3390\/antibiotics11010104","volume":"11","author":"JV Rogers","year":"2022","unstructured":"Rogers, J. V., Hall, V. L. & McOsker, C. C. Crumbling the castle: targeting DNABII proteins for collapsing bacterial biofilms as a therapeutic approach to treat disease and combat antimicrobial resistance. Antibiotics 11, 104 (2022).","journal-title":"Antibiotics"},{"key":"1169_CR101","doi-asserted-by":"publisher","first-page":"1490","DOI":"10.3390\/antibiotics12101490","volume":"12","author":"ZDC Burke","year":"2023","unstructured":"Burke, Z. D. C. et al. Monoclonal antibody disrupts biofilm structure and restores antibiotic susceptibility in an orthopedic implant infection model. Antibiotics 12, 1490 (2023).","journal-title":"Antibiotics"},{"key":"1169_CR102","doi-asserted-by":"publisher","first-page":"126719","DOI":"10.1016\/j.micres.2021.126719","volume":"246","author":"G Horna","year":"2021","unstructured":"Horna, G. & Ruiz, J. Type 3 secretion system of Pseudomonas aeruginosa. Microbiol. Res. 246, 126719 (2021).","journal-title":"Microbiol. Res."},{"key":"1169_CR103","doi-asserted-by":"publisher","first-page":"2151","DOI":"10.2147\/IDR.S193649","volume":"12","author":"L Xue","year":"2019","unstructured":"Xue, L. et al. Staphyloxanthin: a potential target for antivirulence therapy. Infect. Drug Resist. 12, 2151\u20132160 (2019).","journal-title":"Infect. Drug Resist."},{"key":"1169_CR104","doi-asserted-by":"publisher","first-page":"113281","DOI":"10.1016\/j.celrep.2023.113281","volume":"42","author":"AE Campbell","year":"2023","unstructured":"Campbell, A. E. et al. Variable staphyloxanthin production by Staphylococcus aureus drives strain-dependent effects on diabetic wound-healing outcomes. Cell Rep. 42, 113281 (2023).","journal-title":"Cell Rep."},{"key":"1169_CR105","doi-asserted-by":"publisher","first-page":"397","DOI":"10.3390\/antibiotics9070397","volume":"9","author":"M Sarshar","year":"2020","unstructured":"Sarshar, M. et al. FimH and anti-adhesive therapeutics: a disarming strategy against uropathogens. Antibiotics 9, 397 (2020).","journal-title":"Antibiotics"},{"key":"1169_CR106","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41586-024-07681-w","volume":"632","author":"AK Br\u00f6del","year":"2024","unstructured":"Br\u00f6del, A. K. et al. In situ targeted base editing of bacteria in the mouse gut. Nature 632, 877\u2013884 (2024).","journal-title":"Nature"},{"key":"1169_CR107","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/antibiotics9050269","volume":"9","author":"O Yerushalmy","year":"2020","unstructured":"Yerushalmy, O. et al. The Israeli phage bank (IPB). Antibiotics 9, 269 (2020).","journal-title":"Antibiotics"},{"key":"1169_CR108","doi-asserted-by":"publisher","first-page":"2742","DOI":"10.1093\/jac\/dkae325","volume":"79","author":"C Kolenda","year":"2024","unstructured":"Kolenda, C., Jourdan, J., Roussel-Gaillard, T., Medina, M. & Laurent, F. Phage susceptibility testing methods or \u2018phagograms\u2019: where do we stand and where should we go? J. Antimicrob. Chemother. 79, 2742\u20132749 (2024).","journal-title":"J. Antimicrob. Chemother."},{"key":"1169_CR109","doi-asserted-by":"publisher","unstructured":"McCallin, S., Drulis-Kawa, Z., Ferry, T., Pirnay, J.-P. & Nir-Paz, R. Phages and phage-borne enzymes as new antibacterial agents. Clin. Microbiol. Infect. https:\/\/doi.org\/10.1016\/j.cmi.2023.10.018 (2023).","DOI":"10.1016\/j.cmi.2023.10.018"},{"key":"1169_CR110","doi-asserted-by":"publisher","first-page":"1434","DOI":"10.1038\/s41564-024-01705-x","volume":"9","author":"J-P Pirnay","year":"2024","unstructured":"Pirnay, J.-P. et al. Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat. Microbiol. 9, 1434\u20131453 (2024).","journal-title":"Nat. Microbiol."},{"key":"1169_CR111","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-52192-3","volume":"14","author":"S W\u00fcrstle","year":"2024","unstructured":"W\u00fcrstle, S. et al. Optimized preparation pipeline for emergency phage therapy against Pseudomonas aeruginosa at Yale University. Sci. Rep. 14, 2657 (2024).","journal-title":"Sci. Rep."},{"key":"1169_CR112","doi-asserted-by":"publisher","first-page":"S360","DOI":"10.1093\/cid\/ciad481","volume":"77","author":"J-P Pirnay","year":"2023","unstructured":"Pirnay, J.-P. & Verbeken, G. Magistral phage preparations: is this the model for everyone? Clin. Infect. Dis. 77, S360\u2013S369 (2023).","journal-title":"Clin. Infect. Dis."},{"key":"1169_CR113","doi-asserted-by":"publisher","first-page":"1020","DOI":"10.3390\/v15041020","volume":"15","author":"NM Hitchcock","year":"2023","unstructured":"Hitchcock, N. M. et al. Current clinical landscape and global potential of bacteriophage therapy. Viruses 15, 1020 (2023).","journal-title":"Viruses"},{"key":"1169_CR114","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pbio.3002119","volume":"21","author":"A Petrovic Fabijan","year":"2023","unstructured":"Petrovic Fabijan, A., Iredell, J., Danis-Wlodarczyk, K., Kebriaei, R. & Abedon, S. T. Translating phage therapy into the clinic: recent accomplishments but continuing challenges. PLoS Biol. 21, e3002119 (2023).","journal-title":"PLoS Biol."},{"key":"1169_CR115","doi-asserted-by":"publisher","first-page":"870","DOI":"10.3390\/antibiotics13090870","volume":"13","author":"L Ciu","year":"2024","unstructured":"Ciu, L. et al. A comprehensive review on phage therapy and phages and phage-based drug development. Antibiotics 13, 870 (2024).","journal-title":"Antibiotics"},{"key":"1169_CR116","unstructured":"World Health Organization. 2023 Antibacterial Agents in Clinical and Preclinical Development: An Overview and Analysis (WHO, 2024)"},{"key":"1169_CR117","doi-asserted-by":"publisher","DOI":"10.1186\/s40560-024-00759-7","volume":"12","author":"T Sawa","year":"2024","unstructured":"Sawa, T., Moriyama, K. & Kinoshita, M. Current status of bacteriophage therapy for severe bacterial infections. J. Intensive Care 12, 44 (2024).","journal-title":"J. Intensive Care"},{"key":"1169_CR118","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1038\/s41564-022-01243-4","volume":"7","author":"J Guan","year":"2022","unstructured":"Guan, J. et al. Bacteriophage genome engineering with CRISPR\u2013Cas13a. Nat. Microbiol. 7, 1956\u20131966 (2022).","journal-title":"Nat. Microbiol."},{"key":"1169_CR119","doi-asserted-by":"publisher","first-page":"1172635","DOI":"10.3389\/fmicb.2023.1172635","volume":"14","author":"H-J Jia","year":"2023","unstructured":"Jia, H.-J. et al. Engineering bacteriophages for enhanced host range and efficacy: insights from bacteriophage\u2013bacteria interactions. Front. Microbiol. 14, 1172635 (2023).","journal-title":"Front. Microbiol."},{"key":"1169_CR120","doi-asserted-by":"publisher","first-page":"634","DOI":"10.3390\/ph14070634","volume":"14","author":"B Gibb","year":"2021","unstructured":"Gibb, B., Hyman, P. & Schneider, C. The many applications of engineered bacteriophages \u2014 an overview. Pharmaceuticals 14, 634 (2021).","journal-title":"Pharmaceuticals"},{"key":"1169_CR121","first-page":"7","volume":"11","author":"G-Y Liu","year":"2024","unstructured":"Liu, G.-Y. et al. Antimicrobial resistance crisis: could artificial intelligence be the solution? Mil. Med. Res. 11, 7 (2024).","journal-title":"Mil. Med. Res."},{"key":"1169_CR122","doi-asserted-by":"publisher","first-page":"1171","DOI":"10.3389\/fmicb.2020.01171","volume":"11","author":"J-P Pirnay","year":"2020","unstructured":"Pirnay, J.-P. Phage therapy in the year 2035. Front. Microbiol. 11, 1171 (2020).","journal-title":"Front. Microbiol."},{"key":"1169_CR123","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1038\/s41587-023-01759-y","volume":"42","author":"YE Gencay","year":"2023","unstructured":"Gencay, Y. E. et al. Engineered phage with antibacterial CRISPR\u2013Cas selectively reduce E. coli burden in mice. Nat. Biotechnol. 42, 265\u2013274 (2023).","journal-title":"Nat. Biotechnol."},{"key":"1169_CR124","doi-asserted-by":"publisher","DOI":"10.1128\/cmr.00044-24","volume":"37","author":"M Siopi","year":"2024","unstructured":"Siopi, M. et al. Pharmacokinetics and pharmacodynamics of bacteriophage therapy: a review with a focus on multidrug-resistant Gram-negative bacterial infections. Clin. Microbiol. Rev. 37, e0004424 (2024).","journal-title":"Clin. Microbiol. Rev."},{"key":"1169_CR125","doi-asserted-by":"publisher","first-page":"702","DOI":"10.1016\/j.cmi.2023.01.021","volume":"29","author":"SC Nang","year":"2023","unstructured":"Nang, S. C. et al. Pharmacokinetics\/pharmacodynamics of phage therapy: a major hurdle to clinical translation. Clin. Microbiol. Infect. 29, 702\u2013709 (2023).","journal-title":"Clin. Microbiol. Infect."},{"key":"1169_CR126","doi-asserted-by":"publisher","first-page":"1250848","DOI":"10.3389\/fmicb.2023.1250848","volume":"14","author":"Q Yang","year":"2023","unstructured":"Yang, Q., Le, S., Zhu, T. & Wu, N. Regulations of phage therapy across the world. Front. Microbiol. 14, 1250848 (2023).","journal-title":"Front. Microbiol."},{"key":"1169_CR127","doi-asserted-by":"publisher","first-page":"106199","DOI":"10.1016\/j.micpath.2023.106199","volume":"181","author":"Y Ali","year":"2023","unstructured":"Ali, Y., Inusa, I., Sanghvi, G., Mandaliya, V. B. & Bishoyi, A. K. The current status of phage therapy and its advancement towards establishing standard antimicrobials for combating multi drug-resistant bacterial pathogens. Microb. Pathog. 181, 106199 (2023).","journal-title":"Microb. Pathog."},{"key":"1169_CR128","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1186\/s12929-023-00919-1","volume":"30","author":"H Liu","year":"2023","unstructured":"Liu, H. et al. Therapeutic potential of bacteriophage endolysins for infections caused by Gram-positive bacteria. J. Biomed. Sci. 30, 29 (2023).","journal-title":"J. Biomed. Sci."},{"key":"1169_CR129","doi-asserted-by":"publisher","first-page":"1250848","DOI":"10.3389\/fmicb.2022.841905","volume":"13","author":"R Schuch","year":"2022","unstructured":"Schuch, R., Cassino, C. & Vila-Farres, X. Direct lytic agents: novel, rapidly acting potential antimicrobial treatment modalities for systemic use in the era of rising antibiotic resistance. Front. Microbiol. 13, 1250848 (2022).","journal-title":"Front. Microbiol."},{"key":"1169_CR130","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1093\/cid\/ciae043","volume":"78","author":"VG Fowler","year":"2024","unstructured":"Fowler, V. G. et al. Exebacase in addition to standard-of-care antibiotics for Staphylococcus aureus bloodstream infections and right-sided infective endocarditis: a phase 3, superiority-design, placebo-controlled, randomized clinical trial (DISRUPT). Clin. Infect. Dis. 78, 1473\u20131481 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1169_CR131","doi-asserted-by":"publisher","first-page":"04135","DOI":"10.7189\/jogh.14.04135","volume":"14","author":"Y Chen","year":"2024","unstructured":"Chen, Y. et al. The global burden and trend of Clostridioides difficile and its association with world antibiotic consumption, 1990\u20132019. J. Glob. Health 14, 04135 (2024).","journal-title":"J. Glob. Health"},{"key":"1169_CR132","doi-asserted-by":"publisher","first-page":"1462","DOI":"10.1093\/cid\/ciad792","volume":"78","author":"PC Okhuysen","year":"2024","unstructured":"Okhuysen, P. C. et al. A randomized, double-blind, phase 3 safety and efficacy study of ridinilazole versus vancomycin for treatment of Clostridioides difficile infection: clinical outcomes with microbiome and metabolome correlates of response. Clin. Infect. Dis. 78, 1462\u20131472 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1169_CR133","doi-asserted-by":"publisher","first-page":"e01395","DOI":"10.1128\/AAC.01395-19","volume":"64","author":"BK Lomeli","year":"2019","unstructured":"Lomeli, B. K. et al. Multiple-ascending-dose phase 1 clinical study of the safety, tolerability, and pharmacokinetics of CRS3123, a narrow-spectrum agent with minimal disruption of normal gut microbiota. Antimicrob. Agents Chemother. 64, e01395\u201319 (2019).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR134","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01621-23","volume":"68","author":"E Bass\u00e8res","year":"2024","unstructured":"Bass\u00e8res, E. et al. Antibacterial activity of ibezapolstat against antimicrobial-resistant clinical strains of Clostridioides difficile. Antimicrob. Agents Chemother. 68, e0162123 (2024).","journal-title":"Antimicrob. Agents Chemother."},{"key":"1169_CR135","doi-asserted-by":"publisher","first-page":"2552","DOI":"10.1021\/acsinfecdis.2c00445","volume":"8","author":"C Hind","year":"2022","unstructured":"Hind, C. et al. Insights into the spectrum of activity and mechanism of action of MGB-BP-3. ACS Infect. Dis. 8, 2552\u20132563 (2022).","journal-title":"ACS Infect. Dis."},{"key":"1169_CR136","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1111\/apt.17049","volume":"56","author":"EL Gulliver","year":"2022","unstructured":"Gulliver, E. L. et al. Review article: the future of microbiome\u2010based therapeutics. Aliment. Pharmacol. Ther. 56, 192\u2013208 (2022).","journal-title":"Aliment. Pharmacol. Ther."},{"key":"1169_CR137","doi-asserted-by":"publisher","first-page":"757","DOI":"10.1007\/s40259-023-00617-2","volume":"37","author":"P Berry","year":"2023","unstructured":"Berry, P. & Khanna, S. Recurrent Clostridioides difficile infection: current clinical management and microbiome-based therapies. BioDrugs 37, 757\u2013773 (2023).","journal-title":"BioDrugs"},{"key":"1169_CR138","doi-asserted-by":"publisher","first-page":"2186671","DOI":"10.1080\/19490976.2023.2186671","volume":"15","author":"EE Fekete","year":"2023","unstructured":"Fekete, E. E., Figeys, D. & Zhang, X. Microbiota-directed biotherapeutics: considerations for quality and functional assessment. Gut Microbes 15, 2186671 (2023).","journal-title":"Gut Microbes"},{"key":"1169_CR139","first-page":"CD013871","volume":"4","author":"NZ Minkoff","year":"2023","unstructured":"Minkoff, N. Z. et al. Fecal microbiota transplantation for the treatment of recurrent Clostridioides difficile (Clostridium difficile). Cochrane Database Syst. Rev. 4, CD013871 (2023).","journal-title":"Cochrane Database Syst. Rev."},{"key":"1169_CR140","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1007\/s40265-022-01832-x","volume":"83","author":"AJ Gonzales-Luna","year":"2023","unstructured":"Gonzales-Luna, A. J., Carlson, T. J. & Garey, K. W. Emerging options for the prevention and management of Clostridioides difficile infection. Drugs 83, 105\u2013116 (2023).","journal-title":"Drugs"},{"key":"1169_CR141","doi-asserted-by":"publisher","first-page":"175628482412530","DOI":"10.1177\/17562848241253089","volume":"17","author":"HL DuPont","year":"2024","unstructured":"DuPont, H. L., DuPont, A. W. & Tillotson, G. S. Microbiota restoration therapies for recurrent Clostridioides difficile infection reach an important new milestone. Therap. Adv. Gastroenterol. 17, 17562848241253089 (2024).","journal-title":"Therap. Adv. Gastroenterol."},{"key":"1169_CR142","doi-asserted-by":"publisher","first-page":"1527","DOI":"10.1007\/s40265-022-01797-x","volume":"82","author":"S Khanna","year":"2022","unstructured":"Khanna, S. et al. Efficacy and safety of RBX2660 in PUNCH CD3, a phase III, randomized, double-blind, placebo-controlled trial with a bayesian primary analysis for the prevention of recurrent Clostridioides difficile infection. Drugs 82, 1527\u20131538 (2022).","journal-title":"Drugs"},{"key":"1169_CR143","doi-asserted-by":"publisher","first-page":"583","DOI":"10.1016\/j.chom.2022.03.016","volume":"30","author":"M Dsouza","year":"2022","unstructured":"Dsouza, M. et al. Colonization of the live biotherapeutic product VE303 and modulation of the microbiota and metabolites in healthy volunteers. Cell Host Microbe 30, 583\u2013598.e8 (2022).","journal-title":"Cell Host Microbe"},{"key":"1169_CR144","doi-asserted-by":"publisher","first-page":"3137","DOI":"10.2147\/IDR.S400570","volume":"16","author":"S Nagarakanti","year":"2023","unstructured":"Nagarakanti, S. & Orenstein, R. Treating Clostridioides difficile: could microbiota-based live biotherapeutic products provide the answer? Infect. Drug Resist. 16, 3137\u20133143 (2023).","journal-title":"Infect. Drug Resist."},{"key":"1169_CR145","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-022-07256-y","volume":"22","author":"R Orenstein","year":"2022","unstructured":"Orenstein, R. et al. Durable reduction of Clostridioides difficile infection recurrence and microbiome restoration after treatment with RBX2660: results from an open-label phase 2 clinical trial. BMC Infect. Dis. 22, 245 (2022).","journal-title":"BMC Infect. Dis."},{"key":"1169_CR146","doi-asserted-by":"publisher","DOI":"10.1128\/spectrum.00517-23","volume":"11","author":"SP Sambol","year":"2023","unstructured":"Sambol, S. P. et al. Effective colonization by nontoxigenic Clostridioides difficile REA strain M3 (NTCD-M3) spores following treatment with either fidaxomicin or vancomycin. Microbiol. Spectr. 11, e0051723 (2023).","journal-title":"Microbiol. Spectr."},{"key":"1169_CR147","doi-asserted-by":"publisher","first-page":"71","DOI":"10.4291\/wjgp.v14.i4.71","volume":"14","author":"CK Murphy","year":"2023","unstructured":"Murphy, C. K. et al. Novel, non-colonizing, single-strain live biotherapeutic product ADS024 protects against Clostridioides difficile infection challenge in vivo. World J. Gastrointest. Pathophysiol. 14, 71\u201385 (2023).","journal-title":"World J. Gastrointest. Pathophysiol."},{"key":"1169_CR148","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1093\/cid\/ciae467","volume":"80","author":"DM Drekonja","year":"2024","unstructured":"Drekonja, D. M. et al. A randomized controlled trial of efficacy and safety of fecal microbiota transplant for preventing recurrent Clostridioides difficile infection. Clin. Infect. Dis. 80, 52\u201360 (2024).","journal-title":"Clin. Infect. Dis."},{"key":"1169_CR149","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1038\/s41579-020-0340-0","volume":"18","author":"U Theuretzbacher","year":"2020","unstructured":"Theuretzbacher, U. et al. Critical analysis of antibacterial agents in clinical development. Nat. Rev. Microbiol. 18, 286\u2013298 (2020).","journal-title":"Nat. Rev. Microbiol."}],"container-title":["Nature Reviews Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01169-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01169-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,7,16]],"date-time":"2025-07-16T12:03:02Z","timestamp":1752667382000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41579-025-01169-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,4,10]]},"references-count":149,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025,8]]}},"alternative-id":["1169"],"URL":"https:\/\/doi.org\/10.1038\/s41579-025-01169-8","relation":{},"ISSN":["1740-1526","1740-1534"],"issn-type":[{"value":"1740-1526","type":"print"},{"value":"1740-1534","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,4,10]]},"assertion":[{"value":"4 March 2025","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 April 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The author declares no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}